08:50 EDT Omeros (OMER) up 124% at $9.20 after entering license agreement for zaltenibert
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Novo Nordisk, Omeros enter asset purchase, license agreement for zaltenibert
- Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH
- Promising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy Rating
- Omeros announces publication of narsoplimab survival outcomes in TA-TMA
- Omeros Corporation’s Positive Earnings Call Highlights Progress